PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Moskowitz, Alison J.; Schöder, Heiko; Yahalom, Joachim; McCall, Susan J.; Fox, Stephanie Y.; Gerecitano, John F.; Grewal, Ravinder K.; Hamlin, Paul A.; Horwitz, Steven M.; Kobos, Rachel; Kumar, Anita; Matasar, Matthew J.; Noy, Ariela; Palomba, M. Lia; Perales, Miguel Angel; Portlock, Carol S.; Sauter, Craig S.; Shukla, Neerav; Steinherz, Peter G.; Straus, David J.; Trippett, Tanya M.; Younes, Anas; Zelenetz, Andrew D.; Moskowitz, Craig H.

doi:10.1016/s1470-2045(15)70013-6

Cited by 237 publications

(208 citation statements)

References 22 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…ORR was 76% (PET negativity) either with BV alone or followed by augmented ICE (aug-ICE). At 2 years, EFS was better after ASCT for patients who achieved PET negativity compared to patients who remained PET positive prior to ASCT [61]. In study by Chen et al (2015), BV was used as second line agent prior to ASCT (n 37, R/R HL) and showed ORR of 68% (13 CR, 12 PR), and 32 patients (86%) proceeded to ASCT [62].…”

Section: Introductionmentioning

confidence: 99%

A Review of Autologous Stem Cell Transplantation in Lymphoma

Zahid

Akbar

Amaraneni

et al. 2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of review Chemotherapy remains the first line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin Lymphoma (HL) recur after initial therapy. We want to explore the role of high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. Recent findings There is some utility of upfront consolidation for high risk/high grade B cell lymphoma, mantle cell lymphoma and T cell lymphoma but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL. Summary Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high dose consolidation or in the maintenance setting.

show abstract

Section: Introductionmentioning

confidence: 99%

A Review of Autologous Stem Cell Transplantation in Lymphoma

Zahid

Akbar

Amaraneni

et al. 2017

Curr Hematol Malig Rep

View full text Add to dashboard Cite

show abstract

“…8 An augmented ICE regimen with intensified doses of ifosfamide and etoposide has also been employed for patients with unfavorable risk factors. 74,113 Other commonly used salvage regimens include combinations of platinum agents with cytarabine, such as dexamethasone, cisplatin and cytarabine (DHAP), 114 or etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP). 115,116 Gemcitabine-based chemotherapy regimens have also been developed, such as gemcitabine, dexamethasone and cisplatin (GDP), 117 gemcitabine and vinorelbine (GV), 118 GV with doxorubicin (GVD) 119 or ifosfamide, gemcitabine and vinorelbine (IGeV).…”

Section: Transplantation Strategies For Refractory or Relapsed Hlmentioning

confidence: 99%

“…141,148–151 These findings were corroborated in a recent meta-analysis. 152 Based on the notion that FDG-PET response to salvage therapy is predictive of clinical outcomes, MSKCC has performed two Phase II studies of PET-adapted sequential salvage therapy, 74,113 in which patients with relapsed or refractory HL who did not achieve CR to first salvage therapy were switched to a different salvage regimen prior to ASCT. PET-adapted salvage strategies may increase the proportion of patients achieving FDG-PET negativity and consequently leading to higher chances of cure.…”

Section: Transplantation Strategies For Refractory or Relapsed Hlmentioning

confidence: 99%

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

Karantanos

Politikos

Boussiotis

2017

BLCTT

View full text Add to dashboard Cite

Hodgkin’s lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which remains the standard of care with curative potential for refractory or relapsed HL. Nevertheless, a significant percentage of such patients will progress after ASCT, and allogeneic hematopoietic stem cell transplantation remains the only curative approach in that setting. Recent advances in the pathophysiology of refractory or relapsed HL have provided the rationale for the development of novel targeted therapies with potent anti-HL activity and favorable toxicity profile, in contrast to cytotoxic chemotherapy. Brentuximab vedotin and programmed cell death-1-based immunotherapy have proven efficacy in the management of refractory or relapsed HL, whereas several other agents have shown promise in early clinical trials. Several of these agents are being incorporated with transplantation strategies in order to improve the outcomes of refractory or relapsed HL. In this review we summarize the current knowledge regarding the mechanisms responsible for the development of refractory/relapsed HL and the outcomes with current treatment strategies, with an emphasis on targeted therapies and hematopoietic stem cell transplantation.

show abstract

“…While many platinum-based and gemcitabine-based salvage regimens produce high response rates, exceeding 60%–70%, the complete remission rates achieved with these regimens remains rather low. To improve the CR rate of salvage regimens, brentuximab vedotin was combined with ifosfamide, carboplatin, and etoposide (ICE) (12). In this phase 2 trial brentuximab vedotin was given as a single agent for 2 cycles, with each cycle being 3 weekly doses of brentuximab vedotin followed by one week of rest.…”

Section: Pre Transplant Salvage Therapymentioning

confidence: 99%

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

Alperovich

Younes

2016

The Cancer Journal

Self Cite

View full text Add to dashboard Cite

The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma. CD30 is rarely expressed by normal cells, and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates (ADCs). Brentuximab vedotin is the first ADC to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single agent response rate of 75%. In this review article we will discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed Hodgkin lymphoma.

show abstract

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Cited by 237 publications

References 22 publications

A Review of Autologous Stem Cell Transplantation in Lymphoma

A Review of Autologous Stem Cell Transplantation in Lymphoma

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

Contact Info

Product

Resources

About

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Cited by 237 publications

References 22 publications

A Review of Autologous Stem Cell Transplantation in Lymphoma

A Review of Autologous Stem Cell Transplantation in Lymphoma

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin&rsquo;s lymphoma with an emphasis on targeted therapies and transplantation strategies

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

Contact Info

Product

Resources

About

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies